SODIUM OXYBATE (sodium oxybate) by Ascentage Pharma is 12. Approved for cataplexy, excessive daytime sleepiness (eds) in patients 7 years of age, older with narcolepsy (). First approved in 2025.
Drug data last refreshed 19h ago
12.1 Mechanism of Action LUMRYZ is a CNS depressant. The mechanism of action of LUMRYZ in the treatment of narcolepsy is unknown. Sodium oxybate is the sodium salt of gamma-hydroxybutyrate (GHB), an endogenous compound and metabolite of the neurotransmitter GABA. It is hypothesized that the…
Worked on SODIUM OXYBATE at Ascentage Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
A Switch Study From High-Sodium Oxybate to Xywav to Evaluate Changes in Blood Pressure in Participants With Narcolepsy
Treatment of REM Sleep Behavior Disorder (RBD) With Sodium Oxybate
Sodium Oxybate in Patients With Chronic Fatigue Syndrome.
Safety and Tolerability Study Comparing Sodium Oxybate Given as an Oral Solution to a Single-blinded Combination of Oral Tablets Plus Oral Solution in Subjects With Fibromyalgia
Sodium Oxybate in Patients With Alternating Hemiplegia of Childhood (AHC-SO)
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo